The answer to this question likely will be shaped in part by a new multilateral working group that will include not only representatives from the U.S. (U.S. Department of Justice Antitrust Division, and Offices of State Attorneys General), but also Canada (Canadian Competition Bureau), Europe… Read More »What is the FTC’s stance on pharmaceutical mergers?
To get people vaccinated for COVID-19, a lot of things have to go right. First, you have to have purchased the vaccine. Second, you need a supply chain to be able to deliver the vaccine. Third (or perhaps first) you need people who actually are… Read More »Why are Israel’s COVID-19 vaccination rates so high?
A number of different federal agencies buy prescription drugs. However, the price at which these pharmaceuticals are purchased varies dramatically. To quantify this variation, a 2021 report from the Congressional Budget Office examines the following prices: Medicare Part D: the prescription drug program for Medicare… Read More »How much does the U.S. federal government pay for pharmaceuticals?
Conventional wisdom holds that the U.S. has become more and more partisan and the views of both Democrats and Republicans have become less moderate over time. Is that the case with respect to views on health policy? A paper in JAMA last week by Blendon… Read More »Democrats vs. Republicans: Health Policy Battle Royale
That is the title of an article by Angela Maas in Radar on Specialty pharmacy (reprinted here). A few excerpts: “Although state governments frequently pay for health care through programs such as Medicaid, in the past, state governments have not manufactured drugs,” says Jason Shafrin,… Read More »Law Will Allow Calif. to Produce, Distribute Biosimilars, Generics
Last week I reviewed an article on some of the potential positives and negatives of large, integrated health systems. A recent 60 Minutes episode talks about some of the perils by examining how Sutter health system has become a near monopoly provider in Northern California.… Read More »The perils of health systems
Integrated delivery networks. IDNs. Accountable Care Organizations. ACOs. Systems of care. Health systems. Whatever you call them, many health policy experts claim that they are the best way for the U.S. health care system to deliver high quality care in a cost-effective manner. But is… Read More »On the promise and peril of health systems
How do you incentivize pharmaceutical companies and researchers to develop new drugs for rare diseases? Drug development is expensive and–by definition–rare diseases have a small market. One solution to this problem is that governments have used orphan drug policies to provide monetary incentives for innovators… Read More »Orphan Drug Policies Around the World
This is the question that a recent paper by Chorniy et al. (2020) attempt to answer. This issue is clearly very relevant as the UK recently has approved the Pfizer/BioNTech vaccine for COVID-19 before the US. Unlike most studies that attempt to examine the relationship… Read More »What is the impact of FDA review time on pharmaceutical R&D investments?
I’ve mentioned this in a number of previous posts, but large scale importation from Canada won’t work to bring down US drugs prices. The US market is too large and Canada does not have the supply to meet US demand. Further, policies proposing drug importation… Read More »Drug importation from Canada won’t work
Last month, the US Food and Drug Administration published a final rule providing guidance for allowing drug importation from Canada. The drugs have to be approved by the Government of Canada’s Health Canada’s Health Products and Food Branch (HPFB) and can be imported by States… Read More »FDA sets guidelines for drug importation from Canada
Earlier this month, the Congressional Budget Office (CBO) gave an update to its federal budget projections between 2020 and 2030. As expected, things look grim for 2020. CBO projects a federal budget deficit of $3.3 trillion in 2020, more than triple the shortfall recorded in… Read More »CBO: COVID-19’s impact on the federal budget
Join me tomorrow, 9/26, 12:00 PM EDT, as PRECISIONheor’s Jason Shafrin and Meena Venkatachalam discuss their recent blog commentary in the health policy journal Health Affairs on how novel methods of Cost-Effectiveness Analysis can be used to expand traditional value frameworks improve health outcomes for underserved communities. Moderated by Precision’s Kelly… Read More »Using HEOR Methods to Reduce Health Inequalities
According to my post yesterday, it may seem like the answer is ‘yes’. The US spends by far the most money per person and the largest share of its economy on health care. While cross-country comparisons often grab the headlines, a New England Journal of… Read More »Do we spend too much on health care?
COVID-19 is a global pandemic and finding a vaccine for COVID-19 would be a boon to societal. The value would be enormous. One study found that the value would be more than 1.1% of GDP. Since global GDP is $87.7 trillion, the value of a… Read More »What is the “reputational value” of developing a COVID vaccine?
President Trump signed 4 executive orders on drug pricing on July 24, 2020. How are they likely to affect drugs prices? Passing along rebates to patients The one of the executive orders mandates that rebates go to reduce patient cost sharing: These middlemen — health… Read More »Trump executive orders on drug prices: Much ado about nothing?
That is the key takeaway from a recent JAMA Viewpoint by Carlo, Barnett and Frank (2020). While there has been some progress, there are still tremendous gaps that need to be addressed. For patients with schizophrenia, bipolar disorder, or other more serious mental health conditions,… Read More »We are failing at treating mental health